Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 With Immediate-Release Carbidopa-Levodopa in Parkinson's Disease Patients With Motor Fluctuations

Trial Profile

A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 With Immediate-Release Carbidopa-Levodopa in Parkinson's Disease Patients With Motor Fluctuations

Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Feb 2019

At a glance

  • Drugs Levodopa/carbidopa (Primary) ; Levodopa/carbidopa (Primary)
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Amneal Pharmaceuticals; IMPAX Laboratories
  • Most Recent Events

    • 16 May 2018 New trial record
    • 07 May 2018 The protocol of this trial has been agreed upon with the Food and Drug Administration (FDA) in a Special Protocol Assessment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top